6-(6-Chloropyridin-3-yl)-2-propan-2-ylpyridazin-3-one | 1197360-12-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-(6-Chloropyridin-3-yl)-2-propan-2-ylpyridazin-3-one
• 英文别名: 6-(6-chloropyridin-3-yl)-2-propan-2-ylpyridazin-3-one
• CAS: 1197360-12-5
• 化学式: C₁₂H₁₂ClN₃O
• 分子量: 249.7
• InChiKey: VJQIKSFPWJMKRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  45.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(6-Chloropyridin-3-yl)-2-propan-2-ylpyridazin-3-one 在 盐酸 、 potassium tert-butylate 作用下， 以 1,4-二氧六环 、 二甲基亚砜 为溶剂， 生成
  参考文献：
  名称：

  4-Phenoxypiperidine pyridazin-3-one histamine H3 receptor inverse agonists demonstrating potent and robust wake promoting activity

  摘要：

  Structure-activity relationships for a series of phenoxypiperidine pyridazin-3-one H3R antagonists/inverse agonists are disclosed. The search for compounds with improved hERG and DAT selectivity without the formation of in vivo active metabolites identified 6-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]- 4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one 17b. Compound 17b met discovery flow criteria, demonstrated potent H3R functional antagonism in vivo in the rat dipsogenia model and potent wake activity in the rat EEG/EMG model at doses as low as 0.1 mg/kg ip. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.026
• 作为产物：
  描述：

  乙基4-(6-氯-3-吡啶基)-4-氧代丁酸酯 在 caesium carbonate 、 一水合肼 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 生成 6-(6-Chloropyridin-3-yl)-2-propan-2-ylpyridazin-3-one
  参考文献：
  名称：

  4-Phenoxypiperidine pyridazin-3-one histamine H3 receptor inverse agonists demonstrating potent and robust wake promoting activity

  摘要：

  Structure-activity relationships for a series of phenoxypiperidine pyridazin-3-one H3R antagonists/inverse agonists are disclosed. The search for compounds with improved hERG and DAT selectivity without the formation of in vivo active metabolites identified 6-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]- 4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one 17b. Compound 17b met discovery flow criteria, demonstrated potent H3R functional antagonism in vivo in the rat dipsogenia model and potent wake activity in the rat EEG/EMG model at doses as low as 0.1 mg/kg ip. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.026

文献信息

• Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands
  申请人：Becknell Nadine C.

  公开号：US20110098269A1

  公开（公告）日：2011-04-28

  The present invention provides compounds according to Formulas I, II, III, IV, V, VI, VII or VIII: their use as H 3 antagonists/inverse agonists, processes for their preparation, and pharmaceutical compositions thereof.

  本发明提供了公式I、II、III、IV、V、VI、VII或VIII的化合物：它们作为H3拮抗剂/逆激动剂的用途、它们的制备方法以及它们的药物组成物。
• SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS
  申请人：Cephalon, Inc.

  公开号：EP2328586A2

  公开（公告）日：2011-06-08
• [EN] SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS<br/>[FR] DÉRIVÉS PYRIDAZINONE SUBSTITUÉS COMME LIGANDS DES RÉCEPTEURS DE L'HISTAMINE-3 (H3)
  申请人：CEPHALON INC

  公开号：WO2009142732A2

  公开（公告）日：2009-11-26

  The present invention provides compounds according to Formulas I, II, III, IV, V, VI, VII or VIII; their use as H3 antagonists/inverse agonists, processes for their preparation, and pharmaceutical compositions thereof.
• 4-Phenoxypiperidine pyridazin-3-one histamine H3 receptor inverse agonists demonstrating potent and robust wake promoting activity
  作者：Robert L. Hudkins、Allison L. Zulli、Reddeppa reddy Dandu、Ming Tao、Kurt A. Josef、Lisa D. Aimone、R. Curtis Haltiwanger、Zeqi Huang、Jacquelyn A. Lyons、Joanne R. Mathiasen、Rita Raddatz、John A. Gruner

  DOI：10.1016/j.bmcl.2012.01.026

  日期：2012.2

  Structure-activity relationships for a series of phenoxypiperidine pyridazin-3-one H3R antagonists/inverse agonists are disclosed. The search for compounds with improved hERG and DAT selectivity without the formation of in vivo active metabolites identified 6-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]- 4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one 17b. Compound 17b met discovery flow criteria, demonstrated potent H3R functional antagonism in vivo in the rat dipsogenia model and potent wake activity in the rat EEG/EMG model at doses as low as 0.1 mg/kg ip. (C) 2012 Elsevier Ltd. All rights reserved.